Pharmaniaga Bhd
KLSE:PHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (0.3), the stock would be worth MYR0.17 (32% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | MYR0.25 |
0%
|
| 3-Year Average | 0.3 | MYR0.17 |
-32%
|
| 5-Year Average | 0.3 | MYR0.17 |
-33%
|
| Industry Average | 1.5 | MYR0.73 |
+197%
|
| Country Average | 2.1 | MYR1.04 |
+323%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
MYR1.9B
|
/ |
Jan 2026
3.9B
|
= |
|
|
MYR1.9B
|
/ |
Dec 2026
4.1B
|
= |
|
|
MYR1.9B
|
/ |
Dec 2027
4.2B
|
= |
|
|
MYR1.9B
|
/ |
Dec 2028
4.5B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| MY |
P
|
Pharmaniaga Bhd
KLSE:PHARMA
|
1.6B MYR | 0.5 | 33.1 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 0.3 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 0.2 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 0.2 | 36.4 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 0.2 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 2.9 | 34.9 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.6B CNY | 0.3 | 10.9 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 0.9 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
61.7B CNY | 1.8 | 21.8 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
60B HKD | 0 | 7.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 2.1 |
| 70th Percentile | 3.7 |
| Max | 5 877.2 |
Other Multiples
Pharmaniaga Bhd
Glance View
Pharmaniaga Bhd.operates as an investment holding company. The company is headquartered in Shah Alam, Selangor. The firm is principally engaged in the research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales, and marketing, as well as community pharmacy. The Company’s segment includes Logistics and distribution, Manufacturing, and Indonesia. The Logistics and distribution segment is engaged in the distribution, trading, and wholesaling of pharmaceutical and medical products as well as supply and installation of medical and hospital equipment in Malaysia. The Manufacturing segment is involved in manufacturing of pharmaceutical products in Malaysia. The Indonesia segment is engaged manufacturing and distribution of pharmaceutical and medical products in Indonesia. Its subsidiaries include Idaman Pharma Manufacturing Sdn. Bhd., Pharmaniaga Manufacturing Berhad, Pharmaniaga LifeScience Sdn. Bhd., Pharmaniaga Logistics Sdn. Bhd., and Pharmaniaga Marketing Sdn. Bhd.
